Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 51

Exploring the brain-gut-microbiota axis to characterize and predict outcome in ...

Abstract Diffuse intrinsic pontine gliomas (DIPGs), represent a group of malignancies with rapid onset of devastating neurologic symptoms associated with the local extension, poor response to adjuvant therapy and a very poor prognosis. Radiotherapy has remained the only modality of treatment with proven transient symptomatic improvement and represents the mainstay ...

Protein degradation as a strategy to target mutant WIP1 in ...

Close to 20% of Diffuse Intrinsic Pontine Gliomas (DIPGs) harbor a mutation in a gene called PPM1D that leads to expression of a truncated form of a protein called WIP1. We have found PPM1D-mutant DIPG cells to require expression of WIP1, rendering it an attractive therapeutic target for these ...

Modulating the DIPG microenvironment with virus and complement inhibitors as ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most formidable challenges faced by pediatric oncologists. For the last 30 years, all treatment approaches for these type of tumors have failed, leaving a terrible prospect of survival at 5 years for these children virtually of zero. Thus, it is clear that new ...

Testing cytotoxic effects and deciphering signalling pathways engaged by a ...

Glioblastoma (GBM) is the most common malignant brain tumor, being highly invasive and not responsive to standard treatment (surgery, radiotherapy, and chemotherapy). Moreover, a major determinant of the high lethality of GBM is the presence of self-renewing, tumorigenic glioblastoma stem-like cells (GSCs) that threateningly support the development and the progressive ...

Unlocking the translational potential of the DIPG epigenome for a ...

Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor with a very poor outlook, with an expected survival of one year. Lack of access to biological tissue sample continues to be the largest barrier to advancing treatment. In 2016, the World Health Organization (WHO) reclassified DIPG tumors as diffuse ...